Marketable Securities

6 Months Ended

Jun. 30, 2025

Investments Debt And Equity Securities [Abstract]

The fair value and amortized cost of available-for-sale marketable securities by major security type are presented in the following tables as of the periods presented:


	June 30, 2025
Type of security	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
U.S. treasury securities	$	32,191	$	26	$	(8	)	$	32,209
Commercial paper		20,202		—		(7	)		20,195
Corporate bonds		15,477		11		(1	)		15,487
U.S. government agency securities		13,385		6		(3	)		13,388
Asset backed securities		5,548		—		—			5,548
Total marketable securities	$	86,803	$	43	$	(19	)	$	86,827


	December 31, 2024
Type of Security	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Estimated Fair Value
U.S. treasury securities	$	22,838	$	25	$	(12	)	$	22,851
Corporate bonds		18,921		20		—			18,941
Commercial paper		12,999		3		(2	)		13,000
U.S. government agency securities		11,402		21		—			11,423
Asset backed securities		7,304		6		—			7,310
Total marketable securities	$	73,464	$	75	$	(14	)	$	73,525

The net amortized cost and fair value of available-for-sale marketable securities are presented in the following table as of the periods presented by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company may intend to sell a security prior to maturity.


	June 30, 2025
	Amortized Cost		Fair Value
Due to mature:
Less than one year	$	86,803	$	86,827
One year through two years		—		—
Total	$	86,803	$	86,827


	December 31, 2024
	Amortized Cost		Fair Value
Due to mature:
Less than one year	$	55,323	$	55,386
One year through two years		18,141		18,139
Total	$	73,464	$	73,525

During the three and six months ended June 30, 2025 and 2024, there were no realized gains or losses on available-for-sale marketable securities.

As of June 30, 2025 and December 31, 2024, no marketable securities had been in a continuous unrealized loss position for more than 12 months and the Company considered any losses to be temporary in nature. The Company reviewed the securities in the tables above and considered the decline in market value for these securities to be primarily attributable to economic and market conditions. As of the periods noted in the tables above, the Company did not intend to sell these securities and did not believe it was more likely than not that it would be required to sell these securities before recovery of their amortized cost basis. Additionally, the Company did not recognize any credit losses related to its marketable securities in an unrealized loss position during any of the periods noted in the table above.

As of June 30, 2025 and December 31, 2024, accrued interest receivables on the Company’s available-for-sale marketable securities were $834 and $532, respectively, and were included within other current assets as presented on its Condensed Consolidated Balance Sheets.

Trevi Therapeutics, Inc. 10-Q